A novel HIV-1 antiviral high throughput screening approach for the discovery of HIV-1 inhibitors

Antiviral Research

Volumn 65, Issue 2, 2005, Pages 107-116

  Blair, Wade S ^a   Isaacson, Jason ^a   Li, Xinqiang ^a   Cao, Joan ^a   Peng, Qinghai ^a   Kong, George F Z ^a   Patick, Amy K ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antiviral screen; Cell based assay; HIV; Reporter virus

Indexed keywords

DELAVIRDINE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; ASSAY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG SCREENING; DUAL REPORTER ASSAY; EMBRYO; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; REPRODUCIBILITY; SIGNAL NOISE RATIO; VALIDATION PROCESS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 13544273297     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2004.11.001     Document Type: Article

References (36)

1. M.E. Adelson, A.L. Pacchia, M. Kaul, R.F. Rando, Y. Ron, S.W. Peltz, and J.P. Dougherty Toward the development of a virus-cell-based assay for the discovery of novel compounds against human immunodeficiency virus type 1 Antimicrob. Agents Chemother. 47 2003 501 508
2. R.K. Akkina, R.M. Walton, M.L. Chen, Q.X. Li, V. Planelles, and I.S. Chen High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G J. Virol. 70 4 1996 2581 2585
3. A. Billich S-1360 Shionogi-GlaxoSmithKline Curr. Opin. Investig. Drugs 4 2 2003 206 209
4. Blair, W.S., Deshpande, M., Fang, H., Lin, P.F., Spicer, T.P., Wallace, O.B., Wang, H., Wang, T., Zhang, Z., Yeung, K.P., 2002. Antiviral indoleoxoacetyl piperizine derivities. US6469006.
5. Blair, W.S., Isaacson, J.S., Cao, J.Q., Patick, A.K., 2004. Dual assay for evaluating activity and cytotoxicity of compounds in the same population of cells. WO2004048613.
6. Blair, W.S., Spicer, T.P., 2001. Reporter viruses and their use in assaying anti-viral compounds. WO0196610 A1.
7. M.R. Boyd Strategies for the identification of new agents for the treatment of AIDS: a national program to facilitate the discovery and preclinical development of new drug candidates for clinical evaluation V.T. DeVita S. Hellman S.A. Rosenberg AIDS Etiology, Diagnosis, Treatment and Prevention 1988 Lippincott Philadelphia 305 317
8. B.K. Chen, K. Saksela, R. Andino, and D. Baltimore Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses J. Virol. 68 2 1994 654 660
9. D.I. Dorsky, and R.D. Harrington An indicator cell assay for T-cell tropic, macrophage-tropic, and primary isolates of HIV-1 based on green fluorescent protein J. Acquir. Immune. Defic. Syndr. 22 3 1999 213 220
10. T. Fujioka, Y. Kashiwada, R.E. Kilkuskie, L.M. Cosentino, L.M. Ballas, J.B. Jiang, W.P. Janzen, I.S. Chen, and K.H. Lee Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids J. Nat. Prod. 57 2 1994 243 247
11. R.J. Gulakowski, J.B. McMahon, P.G. Staley, R.A. Moran, and M.R. Boyd A semiautomated multiparameter approach for anti-HIV drug screening J. Virol. Methods 33 1991 87 100
12. Hanna, G., Lalezari, J., Hellinger, J., Wohl, D., Masterson, T., Fiske, W., Kadow, J., Lin, P., Giordano, M, Colonno, R., Grasela, D., 2004. Antiviral activity, safety, and tolerability of a novel, oral small-molecule HIV-1 attachment inhibitor, BMS-488043, in HIV-1-infected subjects. In: Eleventh Conf. Retrovir. Oppor. Infect. (abstract no. 141).
13. V.A. Johnson, and R.E. Barrington Infectivity assay A. Aldovini B.D. Walker Techniques in HIV Research 1990 Stockton Press New York 71 76
14. P.S. Jones Strategies for antiviral drug discovery Antivir. Chem. Chemother. 9 4 1998 283 302
15. Y. Kashiwada, F. Hashimoto, L.M. Cosentino, C.H. Chen, P.E. Garrett, and K.H. Lee Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents J. Med. Chem. 39 5 1996 1016 1017
16. J. Kimpton, and M. Emerman Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene J. Virol. 66 4 1992 2232 2239
17. P. Kuzmic, C. Hill, and J.W. Janc Practical robust fit of enzyme inhibition data Methods Enzymol. 383 2004 366 381
18. T.S. Lin, R.F. Schinazi, and W.H. Prusoff Potent and selective in vitro activity of 3′-deoxythymidin-2′-ene (3′-deoxy-2′, 3′-didehydrothymidine) against human immunodeficiency virus Biochem. Pharmacol. 36 17 1987 2713 2718
19. P.F. Lin, W. Blair, T. Wang, T. Spicer, Q. Guo, N. Zhou, Y.F. Gong, H.G. Wang, R. Rose, G. Yamanaka, B. Robinson, C.B. Li, R. Fridell, C. Deminie, G. Demers, Z. Yang, L. Zadjura, N. Meanwell, and R. Colonno A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding Proc. Natl. Acad. Sci. U.S.A. 100 19 2003 11013 11018
20. V.J. Merluzzi, K.D. Hargrave, M. Labadia, K. Grozinger, M. Skoog, J.C. Wu, C.K. Shih, K. Eckner, S. Hattox, and J. Adams Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor Science 250 4986 1990 1411 1413
21. H. Mitsuya, and S. Broder Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy- associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides Proc. Natl. Acad. Sci. US.A. 83 6 1986 1911 1915
22. H. Mitsuya, K.J. Weinhold, P.A. Furman, M.H. St. Clair, S.N. Lehrman, R.C. Gallo, D. Bolognesi, D.W. Barry, and S. Broder 3′-Azido-3′- deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy- associated virus in vitro Proc. Natl. Acad. Sci. U.S.A. 82 20 1985 7096 7100
23. H. Miyake, Y. Iizawa, and M. Baba Novel reporter T-cell line highly susceptible to both CCR5- and CXCR4-using human immunodeficiency virus type 1 and its application to drug susceptibility tests J. Clin. Microbiol. 41 6 2003 2515 2521
24. K.A. Page, T. Liegler, and M.B. Feinberg Use of a green fluorescent protein as a marker for human immunodeficiency virus type 1 infection AIDS Res. Hum. Retroviruses 13 13 1997 1077 1081
25. G.C.G. Pais, and T.R. Burke Novel aryl diketo-containing inhibitors of HIV-1 integrase Drugs Future 27 11 2002 1101 1111
26. C.J. Peteropoulos, N.T. Parkin, K.L. Limoli, Y.S. Lie, T. Wrin, W. Huang, H. Tian, D. Smith, G.A. Winslow, D.J. Capon, and J.W. Whitcomb A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1 Antimicrob. Agents Chemother. 44 2000 920 928
27. M. Pirounaki, N.A. Heyden, M. Arens, and L. Ratner Rapid phenotypic drug susceptibility assay for HIV-1 with a CCR5 expressing indicator cell line J. Virol. Methods 85 1/2 2000 151 161
28. D.L. Romero, R.A. Morge, M.J. Genin, C. Biles, M. Busso, L. Resnick, I.W. Althaus, F. Reusser, R.C. Thomas, and W.G. Tarpley Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3-[(1-methylethyl)amino] -pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate J. Med. Chem. 36 10 1993 1505 1508
29. H. Soudeyns, X.I. Yao, Q. Gao, B. Belleau, J.L. Kraus, N. Nguyen-Ba, B. Spira, and M.A. Wainberg Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog Antimicrob. Agents Chemother. 35 7 1991 1386 1390
30. C. Spenlehauer, C.A. Gordon, A. Trkola, and J.P. Moore A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1 Virology 280 2 2001 292 300
31. O.S. Weislow, R. Kiser, D.L. Fine, J. Bader, R.H. Shoemaker, and M.R. Boyd New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity J. Natl. Cancer Inst. 81 8 1989 577 586
32. T. Wang, Z. Zhang, O.B. Wallace, M. Deshpande, H. Fang, Z. Yang, L.M. Zadjura, D.L. Tweedie, S. Huang, F. Zhao, S. Ranadive, B.S. Robinson, Y.F. Gong, K. Ricarrdi, T.P. Spicer, C. Deminie, R. Rose, H.G. Wang, W.S. Blair, P.Y. Shi, P.F. Lin, R.J. Colonno, and N.A. Meanwell Discovery of 4-benzoyl-1-[(4-methoxy- 1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions J. Med. Chem. 46 20 2003 4236 4239
33. Wild, C., Kilgore, N., Reddick, M., Li, F., Salzwedel, K., Matallana, C., Allaway, G., Martin, D., 2003. PA-457 is a small molecule inhibitor of HIV-1 budding/maturation that potently inhibits replication of virus isolates resistant to all classes of approved drugs. In: Tenth Conf. Retrovir. Oppor. Infect. (abstract no. 14).
34. P.G. Yeni, S.M. Hammer, C.C.J. Carpenter, D.A. Cooper, M.A. Fischl, J.M. Gatell, B.G. Gazzard, M.S. Hirsch, D.M. Jacobsen, D.A. Katzenstein, J.S.G. Montaner, D.D. Richman, M.S. Saag, M.S. Schechter, R.T. Schooley, M.A. Thompson, S. Vella, and P.A. Volberding Antiretroviral treatment for adult HIV infection in 2002. Updated Recommendations of the International AIDS Society - USA Panel J. Am. Med. Assoc. 288 2 2002 222 235
35. S.D. Young, S.F. Britcher, L.O. Tran, L.S. Payne, W.C. Lumma, T.A. Lyle, J.R. Huff, P.S. Anderson, D.B. Olsen, and S.S. Carroll L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase Antimicrob. Agents Chemother. 39 1995 2602 2605
36. J.H. Zhang, T.D. Chung, and K.R. Oldenburg A simple statistical parameter for use in evaluation and validation of high throughput screening assays J. Biomol. Screen 4 2 1999 67 73